Previous Article | Next Article ![]()
Journal of Virology, June 1999, p. 5079-5088, Vol. 73, No. 6
Unité d'Oncologie
Virale1 and Unité Rétrovirus
et Transfert Génétique,
Received 25 November 1998/Accepted 12 March 1999
Previous biochemical and genetic evidence indicated that the
functional form of retroviral integrase protein (IN) is a multimer. A
direct demonstration of IN oligomerization during the infectious cycle
was, however, missing, due to the absence of a sensitive detection method. We describe here the generation of infectious human
immunodeficiency virus type 1 (HIV-1) viral clones carrying IN protein
tagged with highly antigenic epitopes. In this setting, we could
readily visualize IN both in producer cells and in viral particles.
More interestingly, we detected IN oligomers, the formation of which
was dependent on disulfide bridges and took place inside virions.
Additionally, expression of a tagged HIV-1 IN in the absence of other
viral components resulted in almost exclusive nuclear
accumulation of the protein. Mutation of a conserved cysteine in the
proposed dimer interface determined the loss of viral infectivity, associated with a reduction of IN oligomer formation and the
redistribution of the mutated protein in the nucleus and cytoplasm.
Epitope tagging of HIV-1 IN expressed alone or in the context of a
replication-competent viral clone provides powerful tools to validate
debated issues on the implication of this enzyme in different steps of
the viral cycle.
Retroviral integrase (IN) is the
enzyme responsible for the insertion of a DNA copy of the viral genome
in the host DNA, a crucial step of the retroviral cycle (see references
2, 3, and 6 for reviews). IN
catalyzes the two steps of the retroviral integration process. The
first step consists in the elimination of 2 nucleotides from each 3'
end of the proviral DNA. In the second step, the resulting 3'-OH ends
of the viral DNA are covalently joined to newly created 5' ends in the
target DNA (12, 18, 22, 45, 47, 57, 61). Viral IN is
expressed and incorporated into viral particles as part of a large
Gag-Pol polyprotein precursor, which is processed by the viral protease
in the late stages of assembly (39, 58). After viral entry
in the target cell, IN remains associated with a large nucleoprotein
preintegration complex (PIC), which delivers the viral genome to
the nucleus (5, 11, 13, 23, 44, 48, 52). Besides IN,
other viral proteins that were found to cofractionate with human
immunodeficiency virus type 1 (HIV-1) PICs are the matrix,
the reverse transcriptase, the viral protein R (Vpr), and, to a lesser
extent, the nucleocapsid (NC) and capsid (CA) proteins (11, 23,
25, 38, 43, 44, 52). In addition, host proteins such as HMG I(Y)
and Ini1, the human homologue of yeast transcription factor SNF5,
although dispensable for IN activity in vitro, can stimulate IN
activity under certain conditions (43) or restore function
to salt-treated PICs (24). Access of PICs to the nuclear
compartment differentiates oncoretroviruses, which need mitotic nuclear
envelope breakdown (37, 54), from lentiviruses, which are
capable of infecting nonmitotic cells (10, 49, 63). Three
viral proteins, matrix (MA), IN, and Vpr, have been suggested to be
implicated in the nuclear transport of HIV-1 PICs; however, their roles
remain disputed (8-10, 15, 25, 28-35, 38, 62). Nuclear
localization signals (NLSs) were described within the sequence of HIV-1
IN, but alteration of these putative signals was reported to interfere
with a phase of the viral cycle different from the nuclear import of
PICs (16, 32). Expression of HIV-1 IN fused to Another intriguing issue of retroviral IN proteins consists in the
oligomerization status of IN. Detailed biochemical and genetic analysis
indicates that IN proteins form multimers; however, the number of
monomers involved and the conditions under which different-order
oligomerization takes place are debated (4). Retroviral IN
proteins comprise three functionally distinct domains: the N-terminal
domain, which contains a zinc finger-like motif; the catalytic core
domain; and the C-terminal DNA-binding domain (6). Sequences
throughout IN have been pointed out as important for multimerization
(1, 19, 21, 65). Dimers and/or tetramers of recombinant IN
proteins were observed in solution (40, 41, 57, 60).
The use of the yeast two-hybrid system, besides revealing homomeric interactions for HIV-1 IN, helped in defining some of the
sequences involved (42). The most convincing argument that the functional form of IN is a multimer is provided by the
complementation of pairs of inactive proteins carrying mutations or
deletions in separate functional domains (20, 21, 27, 59).
The crystal structure of the core domain of HIV-1 IN (19)
shows that it consists of a five-strand To follow IN through the viral cycle and directly visualize possible
multimeric forms of the enzyme, we constructed a replication-competent HIV-1 clone carrying a tagged IN. We show here that HIV-1 IN forms dimers and higher-order multimers in viral particles. Interestingly, oligomerization of IN was found to be dependent on disulfide bridge formation. We also confirmed the intrinsic karyophilic properties of
HIV-1 IN, which displayed an almost exclusively nuclear localization when expressed in the absence of other viral products. Additionally, we
report that mutation of a conserved cysteine (C130) in the proposed
dimer interface results in loss of viral infectivity, reduced dimer
formation, and altered subcellular localization of the enzyme. Tagged
viruses provide a valuable tool for additional characterization of IN,
for studying the intracellular trafficking of the PICs, and for PIC
isolation and in vitro analysis.
Plasmid construction and mutagenesis.
The HIV-1 BRU
infectious molecular clone was used to express the viral IN fused to
the hemagglutinin (HA) or the Flag epitope. Both epitopes were
fused either at the N or at the C terminus of IN. The procedure
consisted of amplification by PCR with two sets of primers. For fusion
at the C terminus of IN, we used a primer encoding part of the sequence
of the fusion epitope in its 5' portion and complementary to the
C-terminal sequence of IN in the 3' portion (primer HA1 for the HA
epitope or Flag1 for the Flag epitope) in combination with a
primer overlapping the PflMI restriction site located
upstream of the IN sequence (primer Pflm1). In a separate reaction, a
primer encoding the remaining portion of the tagging epitope
including a short overlap with the tagging primer and complementary to
the sequence downstream of IN (HA2 or Flag2) was used with the Pflm2
primer, which overlaps the PflMI site downstream of IN.
Equimolar PCR products obtained in the two initial reactions were mixed
and amplified with the Pflm1 and Pflm2 primers, producing a fragment
which upon digestion with PflMI could be used to
replace the original BRU sequence. A similar approach was used to
insert the tagging sequences near the N terminus of the IN coding
region. In this setting, the Pflm1 primer was used in combination with
the HA.N1 or the Flag.N1 primer, while the Pflm2 primer was
combined with the HA.N2 or the Flag.N2 primer. Addition of the HA tag
creates an NheI site, while the Flag sequence forms a
ClaI site if inserted at the N terminus and a
SpeI site if inserted at the C terminus of IN. All
constructions were confirmed by DNA sequencing of the entire
PCR-amplified fragment. The sequences of the primers used were as
follows: Pflm1, 5' TTCTAAAAGAACCAGTACATGGAGTGTATTAT 3';
Pflm2, 5' CTCTTTTTCCTCCATTCTATGGAGACTCCCTG 3'; HA1,
5'
ACC TAGGCTAGCGTAATCTGGAACATCGTATGGGTAATCCTCATCCTGT CTACTTGCC
3'; HA2, 5' GTTCCAGATTACGCTAGCCTAGGTTAGAACATGGAA 3';
HA.N1, 5'
ATCCAAGCTAGCGTAATCTGGAACATCGTATGGGTATATTCCATCTAAAAATAGTAC 3';
HA.N2, 5' GTTCCAGATTACGCTAGCTTGGATAAGGCCCAA 3'; Flag1,
5' CCACTAGTTACTTGTCATCGTCGTCCTTGTAATCCTCATCCTGTC 3'; Flag2,
5' ACGACGATGACAAGTAACTAGTGGAAAAGTTTAGTAAAAC 3'; Flag.N1,
5' ATCGTCGTCCTTGTAATCGATTCCATCTAAAAAT 3'; and Flag.N2, 5' GAATCGATTACAAGGACGACGATGATAAGGCCCAAGATG 3'. To express
the IN in the absence of other viral products, we used the pFlag
expression vector (55), a kind gift from Serge Benichou
(Institut Cochin, Paris, France), in which we inserted the IN sequence
under the control of the simian virus 40 promoter. The IN sequence was
amplified by PCR with the following primers, which created a
BamHI and an XhoI restriction site at the 5' and
3' ends, respectively, of the IN sequence: Flagint 1, 5'
CCAGGATCCTTTTTAGATGGAATAGATAAG 3'; and Flagint 2, 5'
CTGGCTCGAGCTAATCCTCATCCTGTCTAC 3'. The
Flag-INT expression vector was used for the C130-G
mutagenesis, with the Quick Change mutagenesis kit (Stratagene)
and the primers Cys130+ and Cys130 Cells, virus infection, and reagents.
Human epithelial HeLa
and P4 (HeLa-CD4, long terminal repeat [LTR]-LacZ) cells were grown
in Dulbecco's modified Eagle medium (Gibco), supplemented with
glutamine, antibiotics, and 10% fetal calf serum. P4 cells were
grown in the presence of G418 (1 mg/ml). MT4 lymphoid cells were grown
in RPMI medium supplemented with glutamine, antibiotics, and 10% fetal
calf serum. Viruses were produced by transfection of the plasmids as
described elsewhere (56). Supernatants were analyzed for
HIV-1 p24 antigen content by enzyme-linked immunosorbent assay
(Dupont). P4 cells, plated in 96-well plates, were infected with
different viral doses. Infectivity was measured as previously described
(51). MT4 cells (106) were infected with viral
supernatant corresponding to 30 ng of p24 antigen. Accumulation of p24
in the culture supernatant was measured every 2 or 3 days. The anti-HA
monoclonal antibody (MAb) 12CA5 was a kind gift from Jacob Seeler
(Institut Pasteur, Paris, France). The anti-Gag MAb 25A (anti-CA) and
MAb 18A (anti-MA) were a kind gift from François Traincart
(Institut Pasteur). The rabbit polyclonal anti-Flag antibodies were
from Zymed Laboratories (San Francisco, Calif.), and the mouse
anti-Flag MAb M2 was from Kodak. Cy3-conjugated anti-mouse
immunoglobulin G (IgG) (heavy plus light chain) and
peroxidase-conjugated anti-mouse or anti-rabbit IgG were from Amersham
Life Science. N-Ethylmaleimide (NEM) was from Pierce.
Western blot analysis.
Viral supernatants were collected
from transfected HeLa cells. Cells were lysed in lysis buffer (20 mM
HEPES, 150 mM NaCl, 0.5% Triton X-100) containing standard protease
inhibitors. Proteins corresponding to 30 µg of lysate were analyzed.
Viruses were pelleted by ultracentrifugation (15 min at 60,000 rpm in a
Beckman TL100 centrifuge), and pellets were resuspended in lysis
buffer. For virion lysates, proteins corresponding to the indicated
amounts of p24 were analyzed. When stated, NEM (freshly dissolved in
dimethyl sulfoxide as a 2 M stock solution) was added in lysis buffer
at a 20 mM final concentration. Samples were diluted in loading buffer, in the absence or in the presence of dithiothreitol (DTT) (60 mM final
concentration), and boiled for 5 min. Samples were then run
on a 10 or 12% polyacrylamide gel electrophoresis and transferred to a
nitrocellulose filter (Hybond-C Super; Amersham Life Science) with a semidry electrotransfer apparatus (Bio-Rad). Filters
were blocked with 5% nonfat dry milk in phosphate-buffered
saline (PBS)-0.5% Tween 20 and incubated 1 h at room temperature
or overnight at 4°C in PBS-Tween-milk with the indicated antibodies
(final concentrations for each antibody are as follows: anti-Gag 25A
plus 18A, 0.5 µg/ml; anti-HA 12CA5, 2 µg/ml; anti-Flag, 2 µg/ml).
After three washes with PBS-0.1% Tween, the filters were incubated
with a 1:2,500 solution of horseradish peroxidase-conjugated anti-mouse
or anti-rabbit IgG in PBS-Tween-milk. After three washes, bound
peroxidase activity was revealed with the ECL chemiluminescence kit
(Amersham Life Science) and exposure on Hyperfilm (Amersham Life Science).
Immunoprecipitation.
Viral lysates were prepared as
described above. Rabbit anti-Flag polyclonal antibodies or mouse
anti-HA MAbs were covalently cross-linked to protein A-Sepharose with
dimethyl pimelimidate. Ten microliters of a packed volume of protein A
beads bound to antibody was incubated with viral lysates containing 200 ng of p24 at room temperature. The beads were then washed three times with lysis buffer, resuspended in denaturing loading buffer, and boiled
for 10 min. Samples were then analyzed by Western blotting as
described above.
Pulse-chase immunoprecipitation.
After starvation in
methionine- and cysteine-free medium, transfected HeLa cells were
metabolically labeled for 1 h with 100 µCi of 35S
Promix (Amersham) per ml. One sample was lysed immediately (time zero),
while others were chased by an excess of unlabeled amino acids for
various lengths of time (1, 2, and 6 h). Cells were lysed in RIPA
buffer (140 mM NaCl, 8 mM Na2HPO4, 2 mM
NaH2PO4, 1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.05% sodium dodecyl sulfate [SDS]) containing
standard protease inhibitors. Cell extracts (corresponding to
106 cells for each time point) were clarified by
centrifugation and incubated overnight with 1 µg of the rabbit
polyclonal anti-Flag antibodies (Zymed), and immune complexes were
precipitated with Dynabeads (DYNAL) coated with anti-rabbit IgG and
washed in RIPA buffer. Samples were subjected to SDS-12%
polyacrylamide gel electrophoresis. After film exposure, the gel was
analyzed with a PhosphorImager (Molecular Dynamics).
Indirect immunofluorescence staining.
HeLa cells (2 × 105) were spread on glass coverslips in 24-well plates,
transfected with the indicated plasmids, and stained for
immunofluorescence 24 to 40 h later. Cells were fixed in 3.7% formaldehyde-PBS for 20 min, washed three times in PBS, and incubated for 10 min in 50 mM NH4Cl to quench free aldehydes. After
one wash in PBS and a 15-min incubation in permeabilization buffer (0.05% saponin, 0.01% Triton X-100, 2% bovine serum albumin, PBS), cells were incubated for 1 h with the first MAb (M2 anti-Flag MAb
at 7.5 µg/ml) in permeabilization buffer. Cells were then washed
three times in permeabilization buffer and incubated with Cy3-conjugated anti-mouse MAbs (Amersham) at a final dilution of 1:200.
Cells were washed three times in permeabilization buffer and once in
PBS and mounted in 133 mg of Mowiol (Hoechst) per ml-33%
glycerol-133 mM Tris HCl (pH 8.5). Confocal microscopy was performed
with a Leica TCS4D microscope. Series of optical sections at 0.7-µm
intervals were recorded. One representative medial section was mounted
by using Adobe Photoshop software.
Construction of integrase-tagged viral clones.
One of the
major obstacles to the visualization and characterization of HIV-1
integrase protein is the absence of strongly reactive antibodies. To
circumvent this problem, we constructed four proviral clones of HIV-1
in which an antigenic epitope was fused either near the N or at the
C terminus of the IN protein. We chose the influenza virus HA
epitope and the Flag peptide. To reduce perturbation of the
proteolytic cleavage by the protease, the N-terminal fusion inserted
the sequence of the epitopes after the fifth amino acid of IN.
Epitope fusion at the C terminus of IN disrupted the vif
open reading frame after amino acid 17; however, virus production and
infectivity are not sensitive to Vif in the cell lines used in our
study. We obtained the clones BRU-HA.N and BRU-Flag.N,
carrying tagging epitopes fused near the N terminus of IN, and the
clones BRU-HA and BRU-Flag, in which the epitopes are fused
to the C terminus of IN (Fig. 1A).
Effects of IN-epitope fusion on viral infectivity.
To
analyze the impact of the presence of the tags on viral replication, we
transfected HeLa cells with the original BRU and the four tagged
clones. Viral particle production, measured as HIV-1 p24 antigen
release in the culture supernatant, was not affected in the four tagged
viral clones (data not shown). Culture supernatants were normalized for
HIV-1 p24 viral antigen and used to infect P4 (HeLa-CD4+,
LTR-LacZ) and MT4 (T-lymphoblastoid) target cells. The expression of
Viral protein synthesis and maturation of IN-tagged viral
clones.
To study viral protein synthesis for the HA-tagged
proviral clones, transfected HeLa cells were lysed and analyzed
by Western blotting with MAbs for the HIV-1 matrix (MA; p17)
and capsid (CA; p24) proteins. Mature p17 and p24 proteins as
well as partially cleaved precursor proteins were readily detected
after transfection with the wild-type BRU as well as with BRU-HA
and BRU-HA.N plasmid (Fig. 2A).
Quantitatively and qualitatively similar Gag protein profiles were
observed for the wild type and the BRU-HA clone both in cell
lysates and in released viral particles (Fig. 2A), indicating that Gag
protein synthesis and maturation were not affected by addition of
the HA epitope at the C terminus of IN. Interestingly, despite the
lack of infectivity of the N-tagged clone, we noticed only an
accumulation of incompletely cleaved CA protein (still bound to
the p2 spacer peptide) in the cell lysate from the BRU-HA.N clone,
while no difference was noticed in the viral-particle-associated Gag
protein content (Fig. 2A). Fusion of the HA epitope at the N or C
terminus had no major effect on Gag protein production, particle
release, and maturation (Fig. 2A), although N-terminal fusion was
associated with loss of viral infectivity. Transfection of the two
viral clones encoding the Flag fusion epitope at the N or C
terminus of IN (BRU-Flag.N and BRU-Flag) produced Western
blot protein profiles similar to those observed with the HA-tagged
viruses (data not shown). This indicates that the minor proteolytic
defect associated with the N-terminally tagged viruses is independent
of the nature of the tag.
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Oligomerization within Virions and Subcellular
Localization of Human Immunodeficiency Virus Type 1 Integrase
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-Gal
failed to reveal the intrinsic nuclear tropism of IN probably because
of the large size of the resulting fusion protein (46).
Indeed, microinjected IN-glutathione S-transferase fusion
proteins readily migrated to the nuclear compartment (32).
-sheet and six
-helices.
In the crystal, the contact between two monomers formed a large
solvent-excluded interface involving four helices and one
-strand.
The crystal structure was found to be compatible with a model in which
the functional unit for integration is composed of two dimers of IN (19). The more recently described structure of the
N-terminal domain indicates the presence of additional multimerization
determinants (14). Furthermore, zinc binding to the HHCC
sequence located in this domain favors the formation of tetramers and
increases the efficiency of integration in vitro (20, 65).
Despite such detailed biochemical characterization of retroviral IN,
oligomers of the enzyme were not directly visualized during virus
replication because of the lack of a sensitive detection method.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
;
Cys130+, 5' GTACTACGGTTAAGGCAGCTGGTTGGTGGGCGGGAATC 3';
and Cys130
, 5'
GATTCCCGCCCACCAACCAGCTGCCTTAACCGTAGTAC 3'. After the mutagenesis, the BspMI fragment from the mutated Flag-INT vector was
substituted for the corresponding sequence of the BRU clone, to obtain
the mutated BRU-HA.Cys
and BRU-Flag.Cys
full-length clones.
![]()
RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

View larger version (27K):
[in a new window]
FIG. 1.
Construction and infectivity of proviral clones
carrying a tagged IN. (A) Sequences encoding the epitope tags were
inserted by PCR either near the N or at the C terminus of IN with the
HIV-1 BRU infectious molecular clone, yielding the indicated
proviral clones. RT, reverse transcriptase. (B) Infectivity of the
wild-type BRU and of the tagged clones was measured in a single-cycle
assay on P4 (HeLa-CD4+, LTR-LacZ) cells. Values are
expressed as percentages of the BRU virus and represent the means and
the standard deviations of four independent experiments. (C) Viral
infectivity measured as the accumulation of the HIV-1 antigen p24 in
the supernatant of MT4 cells.
-galactosidase in P4 cells is strictly inducible by the HIV transactivator protein Tat, thereby allowing precise quantification of
HIV-1 infectivity based on a single cycle of replication. As shown in
Fig. 1B, the presence of either tag fused at the C terminus of IN did
not perturb single-cycle viral infectivity. In contrast, exposure of P4
cells to the supernatant from HeLa cells transfected with the
N-terminally tagged IN clones did not produce detectable infectious
events. Accordingly, when the transfected cell supernatant was used
to infect MT4 cells (Fig. 1C), HIV p24 antigen readily accumulated in
the MT4 culture supernatant infected with the original BRU clone, as
well as in that infected with the C-terminally tagged clones,
indicating ongoing viral replication. The growth kinetics of these
three viral clones were similar, although the amounts of p24 that
accumulated in the culture supernatants of the two tagged
viruses were decreased six- to ninefold with respect to the
wild-type virus (Fig. 1C). In agreement with the single-cycle data,
exposure of MT4 cells to the supernatant from HeLa cells transfected
with BRU-HA.N and BRU-Flag.N did not result in detectable accumulation of p24 antigen in the culture supernatant, even after 9 days (Fig. 1C). To summarize, while C-terminal tagging of IN had only a
minor effect on viral infectivity and growth kinetics, the same
epitopes fused at the N terminus of IN resulted in noninfectious viral progeny.

View larger version (31K):
[in a new window]
FIG. 2.
Detection of the tagged HIV-1 IN. (A and B) Western
blot analysis of transfected cells and viral particles with antibody
specific for the HIV-1 gag-encoded MA and CA proteins (A)
and for the tagging epitope HA (B). Molecular masses (in
kilodaltons) are indicated on the left side of panels A and B. Cell
lysates containing 30 µg of total proteins and virion preparations
containing 50 ng of p24 were analyzed. CTRL, control. (C) High
sensitivity of Western blot detection of the HA-tagged IN
present in viral particles. The p24 antigen content of viral particles
(in nanograms) is indicated.
Integrase forms protein complexes by disulfide bridges in viral particles. The high sensitivity of Western blot detection shown for the BRU-HA viral clone provides a tool for the biochemical characterization of IN. We investigated the possibility that IN molecules multimerize or form stable protein complexes with viral or cellular proteins. After transfection of HeLa cells with the IN-tagged BRU-HA molecular clone, we analyzed cell lysates and viral particle protein content by Western blotting, in the presence or in the absence of the reducing agent DTT (Fig. 3A). As described above, under reducing conditions the IN-HA fusion protein was readily detected in the viral particles produced by the BRU-HA clone (Fig. 3A, left panel). When the same viral preparations were analyzed under nonreducing conditions, two additional IN-specific, strongly reactive protein bands were observed (Fig. 3A, left panel), indicating that disulfide bridges are required to form two different protein complexes that contain the IN-HA fusion protein. The apparent molecular mass of the prevalent protein complex (70 kDa) would precisely match the size of an IN dimer, while the electrophoretic mobility of the larger product is compatible with a multimeric form of the IN protein or with heterologous protein complexes. A similar protein profile was observed for particles produced by the BRU-Flag clone (data not shown), demonstrating that IN complexes reflect an intrinsic property of IN and are independent of the nature of the fusion epitope.
|
Protein complexes involving IN observed in viral particles are IN multimers. Several reports based on trans-complementation of IN mutants or on structural considerations suggested that the functional form of retroviral integrase is a multimer (20, 21, 27, 59). We used the two replication-competent viral clones BRU-HA and BRU-Flag to investigate the nature of the disulfide-bound protein complexes described above; more specifically, we wanted to determine whether they represent IN homomers. With the aim of producing viral particles carrying different IN molecules that could be distinguished, we cotransfected HeLa cells with equal amounts of BRU-HA and BRU-Flag clones. The resulting virus, named BRU-HA/Flag, was as infectious as the parental tagged viruses in a single-cycle assay (data not shown). We then immunoprecipitated viral proteins with antibodies specific for one tagging epitope and analyzed by Western blotting the immunoprecipitated material with antibodies specific for the other tagging epitope. Protein complexes, immunoprecipitated by one antitag antibody, should be recognized by the other antitag antibody used in the Western blotting only if they contain the two differently tagged IN molecules. As controls, Western blots of nonimmunoprecipitated viral particles produced after transfection of one or both tagged viral clones were run alongside, as well as Western blots of proteins immunoprecipitated with the same antibody used for the detection (Fig. 3C).
Western blot analysis with anti-Flag serum is shown in Fig. 3C, left panel. The anti-Flag serum did not cross-react with HA-tagged IN (lane 1) and could readily detect IN-Flag protein in BRU-HA/Flag viral particles, produced by cotransfection of BRU-HA and BRU-Flag plasmids (lane 2). As expected, immunoprecipitation of BRU-HA viral proteins with anti-Flag serum or anti-HA antibody tested negative on Western blots performed with anti-Flag serum (lanes 3 and 5). Instead, BRU-HA/Flag viral particles were efficiently immunoprecipitated and subsequently revealed by the anti-Flag serum (lane 4). Most importantly, these BRU-HA/Flag viral particles tested strongly positive after immunoprecipitation with anti-HA antibody and Western blot detection with anti-Flag serum (lane 6). Such finding demonstrates that after cotransfection of BRU-HA and BRU-Flag viral clones, particles carrying both IN-HA and IN-Flag fusion proteins are formed and these proteins form multimers. The above results were confirmed by anti-HA Western blot analysis of immunoprecipitated viral proteins (Fig. 3C, right panel). IN-HA proteins produced after transfection of BRU-HA or after BRU-HA/Flag cotransfection were easily detected in viral lysates by Western blots with anti-HA antibody (lanes 7 and 8, respectively). Predictably, immunoprecipitation of BRU-HA viral proteins with anti-Flag serum tested negative in Western blots (lane 9), while the same BRU-HA particle preparation immunoprecipitated and revealed with anti-HA antibody was strongly positive (lane 11). Proteins from BRU-HA/Flag virus could be efficiently immunoprecipitated with both anti-HA antibody (lane 10) and anti-Flag serum (lane 11), validating our finding that IN multimers are abundant in viral particle preparations. To verify that the observed IN multimers are formed in virions that carry the two differently tagged IN proteins and not after particle lysis, culture supernatants produced after independent transfection of BRU-HA and BRU-Flag clones were lysed, mixed, and immunoprecipitated with anti-Flag serum or with anti-HA antibody. As expected, Western blot analysis performed with anti-HA antibody demonstrated that mixed IN multimers were not produced under these conditions (Fig. 3D).Mutation of a conserved cysteine perturbs IN structure and
multimerization.
The above-described results demonstrate that
HIV-1 IN forms stable multimers involving disulfide bridges in viral
particles. With the aim of perturbing the structure and the multimeric
status of the IN enzyme, we mutated a conserved cysteine into a glycine (C130-G) in the third
-helix of IN, in the proposed dimer interface (19), and analyzed the consequences for viral infectivity
and IN multimerization. Such a mutation was inserted in both
replication-competent C-terminally tagged viral clones, producing
BRU-HA.Cys
and BRU-Flag.Cys
.
Strikingly, mutation of the central cysteine completely abolished viral
infectivity in both P4 and MT4 cells (data not shown), demonstrating that conservation of this residue is essential for viral replication. The C130-G mutation was inserted also in a nontagged virus clone, with
consequent total loss of infectivity. To elucidate the impact of C130-G
mutation on viral particle protein content and IN multimerization, p24
antigen-normalized amounts of particles produced by transfection of
BRU-HA and BRU-HA.Cys
were analyzed by
Western blotting (Fig. 4A). When the
Western blot was revealed with anti-Gag antibodies, similar protein
profiles were observed (Fig. 4A, left panel), demonstrating that these particles contain properly processed Gag proteins. When viral particles
were lysed in the presence of DTT (Fig. 4A, middle panel), slightly
less IN protein was detected for the BRU-HA.Cys
viral
clone than for BRU-HA. In addition, lower-molecular-weight protein
degradation products were observed for BRU-HA.Cys
virus, suggesting that the reduced IN-HA detection could be due at
least in part to degradation of the mutant IN protein. Since lysis of
viral particles was performed in the presence of cellular protease
inhibitors, it is likely that the viral protease was responsible for
the observed degradation. When viral pellets were lysed in the absence
of DTT, signals of similar intensity were observed for the monomeric
and dimeric forms of IN for the BRU-HA virus (Fig. 4A, right
panel). Under the same conditions, the BRU-HA.Cys
virus produced a lower-intensity signal corresponding to monomers of IN
and a markedly decreased signal corresponding to dimeric IN
protein. Densitometric analysis of three independent experiments revealed that while for the BRU-HA virus the band corresponding to
IN dimers represented approximately 60% of the intensity of the total
IN signal (monomer plus dimer), for the BRU-HA.Cys
virus the dimer band corresponded to 20% of the total value. The
significant difference in the ratio of the dimer to monomer signals
between BRU-HA and BRU-HA.Cys
viruses indicates
that cysteine 130 is important for IN dimer formation. Similar
observations were made with viruses carrying Flag-IN (data not shown),
indicating that the defect is independent of the tagging epitope.
Cysteine 130 could be one of the residues directly involved in
disulfide bridge formation between two monomers, or it could act
indirectly, by determining the structure of each monomer. A possible
partner for cysteine 130 could be the highly conserved cysteine 65 or
cysteine 56, while it is unlikely that cysteine 130 on each monomer
would interact directly, considering the relative positions of the
monomers in the published structure (19).
|
virus.
The data described above demonstrate that the C130-G substitution
abolished viral infectivity and resulted in partial degradation of IN
in viral particles, suggesting that the viral protease participates in
the degradation process. Our data also indicate that the C130-G mutation reduces IN multimer formation.
Nuclear accumulation of HIV-1 IN protein and altered subcellular localization of the C130-G mutant. The integration process requires that PICs migrate to the nucleus of the newly infected cell. IN contains at least three sequences that resemble typical NLSs (32), suggesting a selective pressure for the accumulation of this enzyme in the nucleus or even the participation of IN in the transport of the large PIC from the cytoplasm to the nucleus. To analyze the intrinsic karyophilic properties of HIV IN, we expressed HIV-1 IN-Flag fusion protein by transfection in HeLa cells, in the absence of other viral proteins. Cells were stained with an anti-Flag antibody and analyzed by confocal microscopy. An intense nuclear staining was observed (Fig. 5A and B), demonstrating that HIV-1 IN expressed in the absence of other viral products specifically accumulates in the nuclear compartment. Since the size of the HIV-1 IN monomer is compatible with its passive diffusion through the nuclear pores (26), this observation implies an active retention of IN in the nucleus.
|
| |
DISCUSSION |
|---|
|
|
|---|
The main goal of our study was to investigate the multimeric status of HIV-1 IN in infectious viral particles. Previous biochemical analysis evidenced homomeric interactions for several retroviral IN proteins, expressed in the absence of other viral components (40-42, 57, 60). trans-complementation of IN proteins affected in different functional domains provided genetic evidence that the functional form of retroviral IN is multimeric (20, 21, 27, 59). Determination of the crystal structure of the core and the N-terminal domains added a new dimension to the evaluation of functional models of IN (14, 19). Direct visualization of multimers in a replication-competent viral setting was hampered by the lack of a sensitive detection method.
The epitope tagging strategy adopted here allowed us to overcome the sensitivity problem and provides a powerful tool for further investigation of IN properties. Two different epitopes were fused to HIV-1 IN in order to rule out the possibility that a specific tagging sequence could be responsible for the observed phenotypes. We showed that while N-terminal tagging abolished infectivity, C-terminal tagging of HIV-1 IN had only a minor effect on viral infectivity. We could readily visualize HIV-1 IN by Western blotting performed on infectious viral particles and producer cell lysates. By coimmunoprecipitation experiments, we demonstrated that HIV-1 IN forms homomers in viral particles. Virions carrying differently tagged IN molecules were produced by cotransfection of the two C-terminally tagged viral clones. Maturation of these precursors led to the formation of chimeric IN multimers, which we could immunoprecipitate with antibody specific for one epitope and subsequently reveal on a Western blot with antibody that recognized the other epitope. Dimers were shown to be the prevalent multimeric form, by Western blot analysis. However, high-molecular-weight products, which could represent higher-order multimers or IN molecules strongly interacting with other proteins, were readily detectable. The amount of multimers present in intact viral particles could even be higher than that observed in our study, since the particle disruption procedure may have perturbed certain interactions.
Interestingly, we found that multimerization takes place inside viral particles and is dependent on disulfide bridges. However, we could not determine whether monomers are held together by intermolecular disulfide bridges or whether disulfide interaction is required to stabilize the structure of each monomer, allowing exposure of interacting surfaces. Of note, these two alternatives are not mutually exclusive. It is also likely that various molecular interactions participate in oligomerization of IN.
Several pieces of evidence provided here argue for the formation of IN oligomers inside viral particles, after proteolytic maturation of the Gag-Pol precursor. First of all, the coimmunoprecipitation experiments clearly demonstrated that chimeric IN oligomers were present in viral particles, while separately produced viral lysates mixed after particle lysis were devoid of chimeric IN oligomers. Oligomers of IN were unaffected by the addition of the thiol-blocking agent NEM to the lysis buffer, confirming that oligomer formation preceded lysis. Mature IN molecules in the cytoplasm of cells transfected with full-length viral clones were found only as monomers, possibly reflecting incompatible redox conditions of this environment. The confined space of the viral particle could also provide favorable conditions for homomeric interaction given the high local concentration of mature monomers. Our observation that IN multimerization takes place within viral particles is compatible with previous models of viral protein interaction. The contribution of Pol sequences to viral precursor assembly is considered to be negligible, and there is no evidence of homomeric interaction at the level of IN sequences in the Gag-Pol precursor (27, 39, 50, 58, 64). The finding that premature termination of protein synthesis in the IN domain resulted in improper PR activation actually suggested a role for the IN domain in delaying protease activation by reducing intermolecular interaction (7).
We also investigated the role of a highly conserved cysteine in IN
multimerization. In an attempt to affect dimer formation, we mutated
the cysteine 130 in the third
-helix of HIV-1 IN, which is part of
the proposed dimer interacting surface (19). Such
substitution abolished viral replication, although it was compatible with viral particle production and maturation. Lysed viral
particles carrying mutated IN sequence were characterized by a decrease
of both multimeric forms of IN. The ratio of monomers to oligomers
clearly differentiated mutant and wild-type viruses. Western blot
analysis of viral particles carrying the C130-G mutant IN revealed the
presence of IN degradation products. Decreased stability of mutant IN
protein was probably also due to structural perturbation.
The use of a tagging epitope to study the karyophilic properties of
HIV-1 IN was the third aim of our study. It was previously demonstrated that avian sarcoma virus IN efficiently penetrated the
nuclear envelope, under the form of a
-Gal fusion protein (46). In the same study, HIV-1 IN fused to
-Gal
localized in the cytoplasm of transfected cells (46). As
already suggested by those authors, the large size of the fusion
protein may be responsible for the nuclear exclusion, since monomers of
IN would be compatible with passive diffusion through the nuclear pores (26). We describe here an almost exclusively nuclear
accumulation of a tagged IN in the absence of other viral components.
Tagging the isolated IN provides a convenient tool to determine the
residues responsible for nuclear import and retention. NLSs have been
described within the HIV-1 IN sequence, which may be validated by using the IN-Flag fusion protein. Although the C130-G mutation does not
directly affect any of the potential NLSs, the mutated proteins were
evenly distributed in the nucleus and the cytoplasm of transfected cells. In the absence of specific NLS, passive diffusion of IN through
the nuclear pores would generate a staining pattern similar to the one
observed for the C130-G mutant. We propose that the loss of nuclear
retention reflects the lesser ability of the C130-G IN protein to form
dimers. With respect to size, IN dimers (or oligomers) must enter the
nucleus through active transport (36). It is also
conceivable that the C130-G mutation indirectly perturbed motifs
that are implicated in nuclear targeting.
The lack of a requirement for other viral components to determine nuclear accumulation of IN shown here may suggest an active role of IN in the nuclear targeting of the PICs. Mutational analysis performed on the tagged IN expressed alone and in a replication-competent viral clone could help determine the role of IN at the level of PICs. Our current goal is to follow the intracellular trafficking of the PICs by using the tagged IN as a marker.
Given the implication of IN in different steps of the viral cycle, it is often difficult to associate a single functional role with a protein domain. The combined use of the two tagged-IN expression vectors could facilitate the evaluation of the impact of specific mutations on the dimerization and the nuclear accumulation properties. We consider that the significantly increased immunogenicity of the tagged IN provides a valuable tool for the study of several currently debated aspects of the retroviral cycle in which IN is implicated.
| |
ACKNOWLEDGMENTS |
|---|
We thank Jean Michel Heard and Francois Clavel for their support and critical suggestions. We thank Emmanuelle Perret for confocal microscopy analysis and Jacob Seeler, François Traincart, and Serge Benichou for the kind gifts of reagents.
F.M. is a fellow of the Agence Nationale de Recherche sur le SIDA (ANRS). C.P. is a fellow of SIDACTION. This work was supported by grants from the ANRS and the Pasteur Institute.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Laboratoire de Recherche Antivirale, IMEA/INSERM Hôpital Bichat-Claude Bernard, 46 rue H. Huchard, 75018 Paris, France. Phone: 33-1-4025 6359. Fax: 33-1-4025 6351. E-mail: mammano{at}bichat.inserm.fr.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Andrake, M. D., and A. M. Skalka.
1995.
Multimerization determinants reside in both the catalytic core and C terminus of avian sarcoma virus integrase.
J. Biol. Chem.
270:29299-29306 |
| 2. |
Andrake, M. D., and A. M. Skalka.
1996.
Retroviral integrase, putting the pieces together.
J. Biol. Chem.
271:19633-19636 |
| 3. | Asante-Appiah, E., and A. M. Skalka. 1997. Mini-review: molecular mechanisms in retrovirus DNA integration. Antiviral Res. 36:139-156[Medline]. |
| 4. | Barsov, E. V., W. E. Huber, J. Marcotrigiano, P. K. Clark, A. D. Clark, E. Arnold, and S. H. Hughes. 1996. Inhibition of human immunodeficiency virus type 1 integrase by the Fab fragment of a specific monoclonal antibody suggests that different multimerization states are required for different enzymatic functions. J. Virol. 70:4484-4494[Abstract]. |
| 5. |
Bowerman, B.,
P. O. Brown,
J. M. Bishop, and H. E. Varmus.
1989.
A nucleoprotein complex mediates the integration of retroviral DNA.
Genes Dev.
3:469-478 |
| 6. | Brown, P. O. 1997. Integration, p. 161-204. In J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Plainview, N.Y. |
| 7. |
Bukovsky, A., and H. Gottlinger.
1996.
Lack of integrase can markedly affect human immunodeficiency virus type 1 particle production in the presence of an active viral protease.
J. Virol.
70:6820-6825 |
| 8. | Bukrinsky, M. I., and O. K. Haffar. 1998. HIV-1 nuclear import: matrix protein is back on center stage, this time together with Vpr. Mol. Med. 4:138-143[Medline]. |
| 9. | Bukrinsky, M. I., S. Haggerty, M. P. Dempsey, N. Sharova, A. Adzhubei, L. Spitz, P. Lewis, D. Goldfarb, M. Emerman, and M. Stevenson. 1993. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 365:666-669[Medline]. |
| 10. |
Bukrinsky, M. I.,
N. Sharova,
M. P. Dempsey,
T. L. Stanwick,
A. G. Bukrinskaya,
S. Haggerty, and M. Stevenson.
1992.
Active nuclear import of human immunodeficiency virus type 1 preintegration complexes.
Proc. Natl. Acad. Sci. USA
89:6580-6584 |
| 11. |
Bukrinsky, M. I.,
N. Sharova,
T. L. McDonald,
T. Pushkarskaya,
W. G. Tarpley, and M. Stevenson.
1993.
Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection.
Proc. Natl. Acad. Sci. USA
90:6125-6129 |
| 12. |
Bushman, F. D.,
T. Fujiwara, and R. Craigie.
1990.
Retroviral DNA integration directed by HIV integration protein in vitro.
Science
249:1555-1558 |
| 13. | Bushman, F. D., and M. D. Miller. 1997. Tethering human immunodeficiency virus type 1 preintegration complexes to target DNA promotes integration at nearby sites. J. Virol. 71:458-464[Abstract]. |
| 14. | Cai, M. L., R. L. Zheng, M. Caffrey, R. Craigie, G. M. Clore, and A. M. Gronenborn. 1997. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat. Struct. Biol. 4:567-577[Medline]. |
| 15. | Camaur, D., P. Gallay, S. Swingler, and D. Trono. 1997. Human immunodeficiency virus matrix tyrosine phosphorylation: characterization of the kinase and its substrate requirements. J. Virol. 71:6834-6841[Abstract]. |
| 16. | Cannon, P. M., E. D. Byles, S. M. Kingsman, and A. J. Kingsman. 1996. Conserved sequences in the carboxyl terminus of integrase that are essential for human immunodeficiency virus type 1 replication. J. Virol. 70:651-657[Abstract]. |
| 17. | Carleton, M., and D. T. Brown. 1997. The formation of intromolecular disulfide bridges is required for induction of the Sindbis virus mutant ts23 phenotype. J. Virol. 71:7696-7703[Abstract]. |
| 18. | Craigie, R., T. Fujiwara, and F. Bushman. 1990. The IN protein of Moloney murine leukemia virus processes the viral DNA ends and accomplishes their integration in vitro. Cell 62:829-837[Medline]. |
| 19. |
Dyda, F.,
A. B. Hickman,
T. M. Jenkins,
A. Engelman,
R. Craigie, and D. R. Davies.
1994.
Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases.
Science
266:1981-1986 |
| 20. |
Ellison, V.,
J. Gerton,
K. A. Vincent, and P. O. Brown.
1995.
An essential interaction between distinct domains of HIV-1 integrase mediates assembly of the active multimer.
J. Biol. Chem.
270:3320-3326 |
| 21. | Engelman, A., F. D. Bushman, and R. Craigie. 1993. Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO J. 12:3269-3275[Medline]. |
| 22. | Engelman, A., K. Mizuuchi, and R. Craigie. 1991. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 67:1211-1221[Medline]. |
| 23. |
Farnet, C., and W. A. Haseltine.
1991.
Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex.
J. Virol.
65:1910-1915 |
| 24. |
Farnet, C. M., and F. D. Bushman.
1997.
HIV-1 cDNA integration requirement of HMG I(Y) protein for function of preintegration complexes in vitro.
Cell
88:483-492[Medline].
|
| 25. |
Farnet, C. M., and W. A. Haseltine.
1990.
Integration of human immunodeficiency virus type 1 DNA in vitro.
Proc. Natl. Acad. Sci. USA
87:4164-4168 |
| 26. | Finlay, D. R., and D. J. Forbes. 1990. Reconstitution of biochemically altered nuclear pores: transport can be eliminated and restored. Cell 60:17-29[Medline]. |
| 27. | Fletcher, T. M., M. A. Soares, S. McPhearson, H. X. Hui, M. A. Wiskerchen, M. A. Muesing, G. M. Shaw, A. D. Leavitt, J. D. Boeke, and B. H. Hahn. 1997. Complementation of integrase function in HIV-1 virions. EMBO J. 16:5123-5138[Medline]. |
| 28. |
Fouchier, R. A.,
B. E. Meyer,
J. H. Simon,
U. Fischer,
A. V. Albright,
F. Gonzalez-Scarano, and M. H. Malim.
1998.
Interaction of the human immunodeficiency virus type 1 Vpr protein with the nuclear pore complex.
J. Virol.
72:6004-6013 |
| 29. | Fouchier, R. A., B. E. Meyer, J. H. Simon, U. Fischer, and M. H. Malim. 1997. HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. EMBO J. 16:4531-4539[Medline]. |
| 30. | Freed, E., G. Englund, F. Maldarelli, and M. A. Martin. 1997. Phosphorylation of residue 131 of HIV-1 matrix is not required for macrophage infection. Cell 88:171-174[Medline]. |
| 31. | Freed, E. O., and M. Martin. 1994. HIV-1 infection of non-dividing cells. Nature 369:107-108[Medline]. |
| 32. |
Gallay, P.,
T. Hope,
D. Chin, and D. Trono.
1997.
HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway.
Proc. Natl. Acad. Sci. USA
94:9825-9830 |
| 33. | Gallay, P., V. Stitt, C. Mundy, M. Oettinger, and D. Trono. 1996. Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import. J. Virol. 70:1027-1032[Abstract]. |
| 34. | Gallay, P., S. Swingler, C. Aiken, and D. Trono. 1995. HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell 80:379-388[Medline]. |
| 35. | Gallay, P., S. Swingler, J. Song, F. Bushman, and D. Trono. 1995. HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell 83:569-576[Medline]. |
| 36. | Gorlich, D. 1998. Transport into and out of the cell nucleus. EMBO J. 17:2721-2727[Medline]. |
| 37. | Hajihosseini, M., L. Iavachev, and J. Price. 1993. Evidence that retroviruses integrate into post-replication host DNA. EMBO J. 12:4969-4974[Medline]. |
| 38. |
Heinzinger, N. K.,
M. I. Bukrinsky,
S. A. Haggerty,
A. M. Ragland,
V. Kewalramani,
M. A. Lee,
H. E. Gendelman,
L. Ratner,
M. Stevenson, and M. Emerman.
1994.
The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells.
Proc. Natl. Acad. Sci. USA
91:7311-7315 |
| 39. | Hunter, E. 1994. Macromolecular interactions in the assembly of HIV and other retroviruses. Semin. Virol. 5:71-83. |
| 40. |
Jenkins, T. M.,
A. Engelman,
R. Ghirlando, and R. Craigie.
1996.
A soluble active mutant of HIV-1 integrase: involvement of both the core and carboxyl-terminal domains in multimerization.
J. Biol. Chem.
271:7712-7718 |
| 41. |
Jones, K. S.,
J. Coleman,
G. W. Merkel,
T. M. Laue, and A. M. Skalka.
1992.
Retroviral integrase functions as a multimer and can turn over catalytically.
J. Biol. Chem.
267:16037-16040 |
| 42. |
Kalpana, G. V., and S. P. Goff.
1993.
Genetic analysis of homomeric interactions of human immunodeficiency virus type 1 integrase using the yeast two-hybrid system.
Proc. Natl. Acad. Sci. USA
90:10593-10597 |
| 43. |
Kalpana, G. V.,
S. Marmon,
W. Wang,
G. R. Crabtree, and S. P. Goff.
1994.
Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5.
Science
266:2002-2006 |
| 44. | Karageorgos, L., P. Li, and C. Burrell. 1993. Characterization of HIV replication complexes early after cell-to-cell infection. AIDS Res. Hum. Retroviruses 9:817-823[Medline]. |
| 45. |
Katzman, M.,
J. P. Mack,
A. M. Skalka, and J. Leis.
1991.
A covalent complex between retroviral integrase and nicked substrate DNA.
Proc. Natl. Acad. Sci. USA
88:4695-4699 |
| 46. | Kukolj, G., K. S. Jones, and A. M. Skalka. 1997. Subcellular localization of avian sarcoma virus and human immunodeficiency virus type 1 integrases. J. Virol. 71:843-847[Abstract]. |
| 47. |
Leavitt, A. D.,
R. B. Rose, and H. E. Varmus.
1992.
Both substrate and target oligonucleotide sequences affect in vitro integration mediated by human immunodeficiency virus type 1 integrase protein produced in Saccharomyces cerevisiae.
J. Virol.
66:2359-2368 |
| 48. |
Lee, M. S., and R. Craigie.
1994.
Protection of retroviral DNA from autointegration: involvement of a cellular factor.
Proc. Natl. Acad. Sci. USA
91:9823-9827 |
| 49. |
Lewis, P., and M. Emerman.
1994.
Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus.
J. Virol.
68:510-516 |
| 50. | Liu, H. M., X. Y. Wu, H. L. Xiao, J. A. Conway, and J. C. Kappes. 1997. Incorporation of functional human immunodeficiency virus type 1 integrase into virions independent of the Gag-Pol precursor protein. J. Virol. 71:7704-7710[Abstract]. |
| 51. |
Mammano, F.,
C. Petit, and F. Clavel.
1998.
Resistance-associated loss of viral fitness in human immunodeficiency virus: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients.
J. Virol.
72:7632-7637 |
| 52. | Miller, M. D., C. M. Farnet, and F. D. Bushman. 1997. Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J. Virol. 71:5382-5390[Abstract]. |
| 53. |
Opstelten, D. J. E.,
M. Wallin, and H. Garoff.
1998.
Moloney murine leukemia virus envelope protein subunits, gp70 and Pr15E, form a stable disulfide-linked complex.
J. Virol.
72:6537-6545 |
| 54. | Roe, T., T. C. Reynolds, G. Yu, and P. O. Brown. 1993. Integration of murine leukemia virus depends on mitosis. EMBO J. 12:2099-2108[Medline]. |
| 55. | Rousset, R., C. Desbois, F. Bantignies, and P. Jalinot. 1996. Effects of NF-kappa B1/p105 processing of the interaction between the HTLV-1 transactivator Tax and the proteasome. Nature 381:328-331[Medline]. |
| 56. | Schwartz, O., V. Maréchal, O. Danos, and J. M. Heard. 1995. Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell. J. Virol. 69:4053-4059[Abstract]. |
| 57. |
Sherman, P. A., and J. A. Fyfe.
1990.
Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity.
Proc. Natl. Acad. Sci. USA
87:5119-5123 |
| 58. | Swanstrom, R., and J. W. Wills. 1997. Synthesis, assembly, and processing of viral proteins, p. 161-204. In J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Plainview, N.Y. |
| 59. | van Gent, D. C., C. Vink, A. A. Groeneger, and R. H. Plasterk. 1993. Complementation between HIV integrase proteins mutated in different domains. EMBO J. 12:3261-3267[Medline]. |
| 60. |
Vincent, K. A.,
V. Ellison,
S. A. Chow, and P. O. Brown.
1993.
Characterization of human immunodeficiency virus type 1 integrase expressed in Escherichia coli and analysis of variants with amino-terminal mutations.
J. Virol.
67:425-437 |
| 61. |
Vink, C.,
D. C. van Gent,
Y. Elgersma, and R. H. Plasterk.
1991.
Human immunodeficiency virus integrase protein requires a subterminal position of its viral DNA recognition sequence for efficient cleavage.
J. Virol.
65:4636-4644 |
| 62. |
von Schwedler, U.,
R. S. Kornblut, and D. Trono.
1994.
The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes.
Proc. Natl. Acad. Sci. USA
91:6992-6996 |
| 63. | Weinberg, J. B., T. J. Matthews, B. R. Cullen, and M. H. Malim. 1991. Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferative human monocytes. J. Exp. Med. 88:1477-1482. |
| 64. | Wu, X. Y., H. M. Liu, H. L. Xiao, J. A. Conway, E. Hunter, and J. C. Kappes. 1997. Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. EMBO J. 16:5113-5122[Medline]. |
| 65. |
Zheng, R. L.,
T. M. Jenkins, and R. Craigie.
1996.
Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity.
Proc. Natl. Acad. Sci. USA
93:13659-13664 |
This article has been cited by other articles: